Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD reviews weight-loss supplement

This article was originally published in The Tan Sheet

Executive Summary

Artis Marketing says it will discontinue and modify advertising claims for its SlimForce7 weight-loss product following a recommendation by the National Advertising Division and referral to the Federal Trade Commission. The division of the Council of Better Business Bureaus found insufficient evidence to support the claim the product is a "treatment aimed at all those who can't seem to lose all the weight they want to lose," among other claims. NAD recommended the Toronto-based company discontinue testimonials and claims suggesting the product, made of six fruits and one algae, will result in weight loss regardless of diet and exercise. NAD's review of SlimForce7 follows a previous attempt to review claims for the product, after which the watchdog was unable to contact the advertiser and referred it to FTC, FDA and relevant Canadian agencies (1"The Tan Sheet" Aug. 17, 2009, In Brief). Subsequently, Artis agreed to participate in the review process, noting it permanently discontinued the original ads and modified many claims at issue. However, NAD found many of the modified claims presented similar concerns

You may also be interested in...

CCA Industries settles Mega-T suit

The marketer of Mega-T brand weight-loss supplements sets aside $2.5 million to distribute among consumers who purchased Mega-T brand products between Sept. 29, 2005, and June 9, 2010. The Common Fund settles a class action lawsuit brought by Denise Wally in California's Superior Court for Los Angeles County. Wally alleged the firm falsely advertised that the supplements would "reduce food cravings," help consumers "lose up to 20 lbs" and enable consumers to burn belly fat without diet or exercise. Consumers who bought any of the supplements in the settlement, including Mega-T Ultra, Mega-T Plus, Mega-T Effervescent, Mega-T Green Tea dietary supplement and Mega-T Dietary Supplement products, could receive up to $60 or more if they submit a claim form. CCA Industries does not admit any guilt or wrongdoing in the settlement. FTC often penalizes weight-loss product makers for claiming products help consumers lose weight without exercise (1"The Tan Sheet" Feb. 22, 2010, In Brief)

NAD alerts FDA, FTC to SlimForce 7 ad

After failing to reach Toronto-based SlimForce 7, which markets a weight-loss product as a supplement under the same name, the Council of Better Business Bureaus unit refers the firm to FDA, the Federal Trade Commission and the Competition Bureau of Canada. NAD said Aug. 10 that a magazine ad claims SlimForce 7 "is a treatment aimed at all those who can't lose weight," enables loss of 11 pounds in one week and modifies the body's metabolism. The claims qualify as "too good to be true" under FTC's reference guide for bogus weight-loss claims (1"The Tan Sheet" Dec. 15, 2003). NAD said SlimForce 7 did not respond to multiple communication attempts

Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch

The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts